Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis

FDA Drug Safety Podcasts

Contenuto fornito da U.S. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Food, Drug Administration, and Center for Drug Evaluation. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da U.S. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Food, Drug Administration, and Center for Drug Evaluation o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

3y ago 3:00

MP3•Pagina principale dell'episodio

Listen to FDA Drug Safety Podcast on due to risk of serious liver injury, FDA restricts use of Ocaliva in primary biliary cholangitis (PBC) patients with advanced cirrhosis

35 episodi

#Science #Fitness #Biology #Medicine #Government #Center For Drug Evaluation #Drug Administration #U.S. Food

Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis

FDA Drug Safety Podcasts

published 3y ago

MP3•Pagina principale dell'episodio

Listen to FDA Drug Safety Podcast on due to risk of serious liver injury, FDA restricts use of Ocaliva in primary biliary cholangitis (PBC) patients with advanced cirrhosis

35 episodi

#Science #Fitness #Biology #Medicine #Government #Center For Drug Evaluation #Drug Administration #U.S. Food

Tutti gli episodi

Benvenuto su Player FM!

Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.

Ascolta più di 500 argomenti

Simile a FDA Drug Safety Podcasts

Podcast che vale la pena ascoltare

FDA Drug Safety Podcasts « » Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis

Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis

Podcast che vale la pena ascoltare

Benvenuto su Player FM!

Simile a FDA Drug Safety Podcasts

Guida rapida

FDA Drug Safety Podcasts « »
Due to risk of serious liver injury, FDA restricts use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) patients with advanced cirrhosis